AGIOS PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2018-03-31 was $516.21M.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2019 was $277.20M, a 46.30% decline from fiscal 2018.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2018 was $516.21M, a 91.01% increase from fiscal 2017.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2017 was $270.25M, a 66.67% increase from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2016 was $162.15M, a 559037.93% increase from fiscal 2015.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2019-12-31 | $277.20M 10-K · filed 2022-02-24 | |
| 2018-12-31 | $516.21M 10-K · filed 2021-02-25 | |
| 2018-03-31 | $516.21M 10-Q · filed 2019-10-31 | |
| 2017-12-31 | $270.25M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $162.15M 10-K · filed 2019-02-14 | |
| 2015-12-31 | $29.00K 10-K · filed 2018-02-14 | |
| 2014-12-31 | $332.62M 10-K · filed 2017-02-16 | |
| 2013-12-31 | $110.98M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |